Cancer treatment intent Flashcards

1
Q

Sytemic chemotherapy different aims

A

Metastatic disease
Adjuvant therapy - clean up micro cancer cells
Primary therapy - neoadjuvant - shrink tumour to allow surgery if inoperable
Chemoprevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Palleative chemo how toxic

A

Treatment should be well tolerated and adverse effects absolutely minimal - should not expense perfomrance status at all

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Ajuvant chemo what intent is

A

Erodicate micrometastatic disease
Greater toxicity accepted - chasing cure
Increased morbidity and mortality (up to 40%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What can neoadjuvant chemo acheive

A

Reduce requiremtn for surgery
Increase likelihood successful debulking
Reduce duration hospital and fitness after surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

When do patients need to starttreatment chemo

A

31 days after agreed treatment plan
62 dyas after 2 week wait referral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is one cycle of chemo

A

every 21 to 28 dyas
6 cycles normally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Low dose therapy when start next cyce

A

When myeloupression recovered eg
neutrophils >1
Platelets >100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Low dose therapy what effect on bone marrow

A

Few days of neutropenia at start then normally recover

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What can give to boost bone marrow recovery

A

IM GCSF - colony stimulating factor
once a day for 7 dyas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is neutropenia minimalised in high dose therapy

A

G-CSF to recover marrow
Autologous stem cells harvested and replaced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What effect does using autologous stem cells have in marrow supression high dose chemo

A

16-21 days to revover from bone marrow supression rather than 6-7 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is dose dense therapy

A

Fractionating intended dose of drug - administer each fraction more frequently
Used in breast and ovarian

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Toxicity of chemo vs anti cancer effect

A

peak plasma concentration determines toxicity therefore less toxic if dose dense chemo
Anti cancer effect if accumulative over time therefore still as effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Benefits of dose dense therapy

A

Overcome drug resistnace
Greater cell kill
Some patietns may show disease progression when getting chemo every 3 weeks and then start to regress on dense dose malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is alternating threapy

A

Different drugs given on alternating schedule eg biweekly
Allows overalp of different drugs w toxicities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why is alternating therapy used

A

No overlapping toxxicity
Overcome drug resistance
Used in haematological cancer

17
Q

Why is when drug is cytotoxic in cell cycle imporant

A

Cells at G2M interface arrested (drugs eg vinca alkaloids) more susceptible to other treatments eg radiotherapy at that stage
If go to G0 - not susetible to chemotherapy

18
Q

WHy need new treatments

A

<10% cancers cured by chemo
Response by cell type and resistance mechanisms

19
Q

Potential routes to new therapies

A

Improve exisitng drugs eg giving pro drug orally rather than infusion
New targets
Targeted therapy
Impove identification of new compunds

20
Q

What determines orgnas susceptibility to metastatses

A

Blood supply
Expression of adhesion molecules on cell surface (eg kidney low expression therefore mets rare)

21
Q

What may tumour shrinkage actually represent

A

May be other cells around the tumour not acutal tumour cells

22
Q

Chemotherapy trial drug stages

A

15 years lab to market
Preclinical - 6.5 years
1.5 years phase 1 - maximum dose of drug tolerated
2 years phase 2 - response assessment at max dose
3.5 years phase 3 - compare to current treatment
1.5 years FDA approval

<1 % drugs leave lab
10-20% get approved

23
Q

What is common toxicity criteria

A

Severity of several hundred side effects from 0-4
Used to evaluate how toxic treatment is

24
Q

What criteria use to assess treatment response

A

RECIST - response evaluation criteria in solid tumours
Alos overall survival rates for drug

25
Q

What evaluate in chemo treatment

A

Overall surivval duration
Response to treatment
Remission rate
Disease free survival
Response duration
WOL
Treatment toxicity

26
Q

What is the role of imaging after cyle 3 of chemotherapy

A

If tumour is responding

27
Q

RECIST criteria

A

Complete response - disappearance of all target lesions
Partial response - at least 30% decrease in long diameter
Progressive - 20% increase in LD of target lesions, 5mm increase or appearance of one or more new lesions
Stbale disease - neither sufficient shrinkage for PR nor PD

28
Q

What rates can use to evaluate cancer

A

Remission rates
Overall surival rates

29
Q

What is complete vs parital remission

A

Complete - remains disease free for 5 years
Partial - some shrinkage but not all signs and symtpoms of cancer c=gone

30
Q

What is disease free survival

A

Length of tume after treatmnet for cancer where patient has no symptoms or signs of disease

31
Q

What is measurable disease

A

At least one lesion that can be accurately measured in at least one dimension eg longest diameter

32
Q

Criteria for measurable disease

A

Lesion must be >10mm CT and MRI assessment, clinical exam
Lesion >20mm on plain X ray

If >5mm slice thick, measurability = lesion w LD>2 x slice thickness

Malignant lymph nodes - short axis diameter >15mm to be considered pathological and measurable

33
Q

What is non measurbale disease in cacner

A

Ascites, peritoneal invasion, effusons, sometimes tumour marker levels

34
Q

What is residual disease

A

When cancer still present at end of chemotherapy
Sometimes difficult to differentiate between normal tissue etc
Adverse prognostic factors
May have more chemotherapy suitable

35
Q

Why can sequencing be improatnt

A

Some cancer MOA may make cell more vulnerable to the next drug but only in that order